Literature DB >> 6315424

In vitro and in vivo synergy between ceftriaxone and aminoglycosides against Pseudomonas aeruginosa.

P Angehrn.   

Abstract

The antibacterial interaction between ceftriaxone and the aminoglycosides tobramycin, gentamicin and amikacin against pseudomonas aeruginosa was investigated in vitro and in experimental systemic infections of the mouse. In vitro synergy was observed in 70% of the strains with tobramycin, 67.5% with gentamicin, and 77.5% with amikacin. Synergistic bactericidal activity was demonstrated with all three aminoglycosides in combination with ceftriaxone. In line with these in vitro results, synergism against most isolates also occurred in mice. In leukopenic mice, the addition of ceftriaxone resulted in a more than 2.5-fold reduction of the aminoglycoside dose necessary for antiinfective protection, although ceftriaxone alone was only marginally active against the pathogen used in immunocompromised animals.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6315424     DOI: 10.1007/bf02013914

Source DB:  PubMed          Journal:  Eur J Clin Microbiol        ISSN: 0722-2211            Impact factor:   3.267


  17 in total

1.  Experimental endocarditis due to Pseudomonas aeruginosa. II. Therapy with carbenicillin and gentamicin.

Authors:  G Archer; F R Fekety
Journal:  J Infect Dis       Date:  1977-09       Impact factor: 5.226

2.  Antibiotic susceptibility testing of Pseudomonas aeruginosa: selection of a control strain and criteria for magnesium and calcium content in media.

Authors:  L B Reller; F D Schoenknecht; M A Kenny; J C Sherris
Journal:  J Infect Dis       Date:  1974-11       Impact factor: 5.226

3.  Comparative in vitro activities of azlocillin-cefotaxime and azlocillin-tobramycin combinations against blood and multi-drug resistant bacterial isolates.

Authors:  R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1982-07       Impact factor: 5.191

4.  Ro 13-9904/001, a novel potent and long-acting parenteral cephalosporin.

Authors:  R Reiner; U Weiss; U Brombacher; P Lanz; M Montavon; A Furlenmeier; P Angehrn; P J Probst
Journal:  J Antibiot (Tokyo)       Date:  1980-07       Impact factor: 2.649

5.  Synergistic activity of carbenicillin and gentamicin in experimental Pseudomonas bacteremia in neutropenic rats.

Authors:  R E Scott; H G Robson
Journal:  Antimicrob Agents Chemother       Date:  1976-10       Impact factor: 5.191

6.  Simultaneous simulation of the serum profiles of two antibiotics and analysis of the combined effect against a culture of Pseudomonas aeruginosa.

Authors:  A Bauernfeind; R Jungwirth; C Petermüller
Journal:  Chemotherapy       Date:  1982       Impact factor: 2.544

7.  Ro 13-9904, a long-acting broad-spectrum cephalosporin: in vitro and in vivo studies.

Authors:  P Angehrn; P J Probst; R Reiner; R L Then
Journal:  Antimicrob Agents Chemother       Date:  1980-12       Impact factor: 5.191

8.  Activity of cefotaxime-aminoglycoside combinations against aminoglycoside-resistant Pseudomonas.

Authors:  P R Murray
Journal:  Antimicrob Agents Chemother       Date:  1980-03       Impact factor: 5.191

9.  In vitro activity of cefoxitin, alone and in combination with aminoglycoside or other beta-lactam antibiotics against common gram-negative pathogens.

Authors:  S M Markowitz; D J Sibilla
Journal:  Chemotherapy       Date:  1983       Impact factor: 2.544

10.  Bactericidal and synergistic activity of moxalactam alone and in combination with gentamicin against Pseudomonas aeruginosa.

Authors:  P K Yu; R S Edson; J A Washington; P E Hermans
Journal:  Antimicrob Agents Chemother       Date:  1983-01       Impact factor: 5.191

View more
  5 in total

1.  The potential uses of ceftriaxone.

Authors:  W M Scheld
Journal:  Eur J Clin Microbiol       Date:  1983-10       Impact factor: 3.267

Review 2.  Ceftriaxone. A reappraisal of its antibacterial activity and pharmacokinetic properties, and an update on its therapeutic use with particular reference to once-daily administration.

Authors:  R N Brogden; A Ward
Journal:  Drugs       Date:  1988-06       Impact factor: 9.546

3.  Ceftriaxone protects against tobramycin nephrotoxicity.

Authors:  D Beauchamp; G Thériault; L Grenier; P Gourde; S Perron; Y Bergeron; L Fontaine; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

4.  In vitro synergy testing of novel antimicrobial combination therapies against Neisseria gonorrhoeae.

Authors:  Lindley A Barbee; Olusegun O Soge; King K Holmes; Matthew R Golden
Journal:  J Antimicrob Chemother       Date:  2014-01-26       Impact factor: 5.790

Review 5.  Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  D M Richards; R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-06       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.